Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8673775 | 0.98 | SIGMAR1 (0.65) | SIGMAR1HRH3SLC6A3KCNH2HTR2A | |
| Hydrochloric Acid SCHEMBL11093610 | 0.96 | SIGMAR1 (0.63) | SIGMAR1HRH3SLC6A3KCNH2HTR2A | |
| SCHEMBL11337893 | 0.86 | SIGMAR1 (0.60) | SIGMAR1HRH3SLC6A3LTA4H | |
| SCHEMBL7378053 | 0.85 | SIGMAR1 (0.55) | SIGMAR1HRH3SLC6A3KCNH2HTR2A | |
| SCHEMBL2327709 | 0.85 | HRH3 (0.59) | SIGMAR1HRH3SLC6A3KCNH2HTR2A | |
| SCHEMBL27907398 | 0.85 | SIGMAR1 (0.67) | SIGMAR1HRH3KCNH2HTR2A | |
| SCHEMBL3718831 | 0.84 | SIGMAR1 (0.60) | SIGMAR1HRH3KCNH2L3MBTL1 | |
| SCHEMBL10731021 | 0.81 | SIGMAR1 (0.66) | SIGMAR1KCNH2HTR2A | |
| SCHEMBL1641681 | 0.80 | ALDH1A1 (0.58) | SIGMAR1HRH3 | |
| Hydrochloric Acid SCHEMBL2429999 | 0.80 | SIGMAR1 (0.56) | SIGMAR1HRH3KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103153063-A | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE INC | 2013-06-12 | — | — | CN | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | SIGMAR1 2358/4885HRH3 2081/4885SLC6A3 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.